Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
Facteur d'impact: 2.9 Facteur d'impact sur 5 ans: 3.72 SJR: 0.736 SNIP: 0.551 CiteScore™: 2.43

ISSN Imprimer: 0743-4863
ISSN En ligne: 2162-660X

Volumes:
Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v14.i4.20
59 pages

Pulmonary Drug Delivery: Physiologic and Mechanistic Aspects

Jianwei Yu
Controlled Drug-Delivery Research Center, Rutgers University, College of Pharmacy, 41 Gordon Road, Suite D, Piscataway, NJ 08854-8067
Yie W. Chien
Controlled Drug-Delivery Research Center, Rutgers University College of Pharmacy, 41 Gordon Road, Suite D, Piscataway, NJ 08854-8067

RÉSUMÉ

Peptide and protein drugs are being used increasingly in major research and development programs in the pharmaceutical industry and are also an important class of therapeutic agents due to advances in genetic engineering and biotechnology. Systemic delivery of these macromolecular drugs, however, has been limited to the parenteral route largely because of their extensive presystemic elimination when taken orally. Faced with this dilemma concerning the systemic delivery of these macromolecules with their unique conformational complexity for therapeutic activity, pharmaceutical scientists have evaluated the potential of various non-oral routes of administration as alternatives. Despite the tremendous efforts that have been devoted to this problem, only limited success has been achieved—mostly with small peptides. Growing attention has been given to the potential of a pulmonary route as an alternative non-invasive means for systemic delivery of peptide/protein-based therapeutic agents due to the fact that the lung provides a huge but extremely thin absorptive mucosal membrane. Although current studies show great promise, pulmonary delivery of therapeutic peptides and proteins is complicated by the complexity of the anatomic structure of the human respiratory system and the influence on drug deposition exerted by respiration. This review discusses the fundamental structure and physiology of the human respiratory system, current methodology used to study pulmonary drug absorption, approaches of drug delivery to the distal lung, and recent progress in pulmonary drug delivery by case studies. The mechanisms of pulmonary drug absorption are also discussed.


Articles with similar content:

Immunological and Toxicological Implications of Short-Term Studies in Animals of Pharmaceutical Aerosol Delivery to the Lungs: Relevance to Humans
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.18, 2001, issue 4
Lucila Garcia-Contreras, Anthony J. Hickey
Transcending the Skin Barrier to Deliver Peptides and Proteins Using Active Technologies
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 4
Haripriya Kalluri, Anushree Herwadkar, Neha Singh, Ajay K. Banga, Advait Badkar
Therapeutic Opportunities in Colon-Specific Drug-Delivery Systems
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 2
Avani Amin, Mayur M. Patel, Tejal Shah
Oral Colon-Specific Drug Delivery of Protein and Peptide Drugs
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Ruchita V. Kumar, Sanjay Singh, Vivek Ranjan Sinha, J. R. Bhinge, Asmita Singh, Rachana Kumria
Lipid-Based Cochleates: A Promising Formulation Platform for Oral and Parenteral Delivery of Therapeutic Agents
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.24, 2007, issue 1
Emilio Squillante, III, Kwon H. Kim, Ravi Rao